Human papillomavirus (HPV) is a viral infection that is passed between people through skin-to-skin contact. They are transmitted through sexual contact and can affect the genitals, mouth, or throat. HPV can also cause cervical cancer and other cancers of the genitals, head, neck, and throat. In addition, the increasing awareness about HPV and the strong efficacy of vaccines toward potentially preventing HPV from progressing into cancer or other indications are driving the growth of the market.
|Unit||Value (USD Million)|
|Key Companies Profiled||2A Pharma ApS (Denmark), Bavarian Nordic A/S (Denmark), BioVaxys Technology Corp. (Canada), F. Hoffmann-La Roche AG (Switzerland), Merck and Co. Inc. (United States), GlaxoSmithKline Plc (United Kingdom), ISA Pharmaceuticals BV (Netherlands), Serum Institute of India Pvt. Ltd. (India) and Walvax Biotechnology Co. Ltd. (China)|
This growth is primarily driven by Increasing Prevalence of Sexual Transmitted Infection and Increasing Initiatives by Government & Private Organizations.
Globally, a noticeable market trend is evident Increasing Research and Development in HPV Major Players, such as 2A Pharma ApS (Denmark), Bavarian Nordic A/S (Denmark), BioVaxys Technology Corp. (Canada), F. Hoffmann-La Roche AG (Switzerland), Merck and Co. Inc. (United States), GlaxoSmithKline Plc (United Kingdom), ISA Pharmaceuticals BV (Netherlands), Serum Institute of India Pvt. Ltd. (India) and Walvax Biotechnology Co. Ltd. (China), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The launch of novel therapies is expected to increase the competition among vendors in the market and may result in vendor fragmentation during the forecast period. In order to differentiate their products from competitors and maintain market rivalry, vendors are also implementing a variety of development techniques. Apart from this, profitable acquisitions and mergers as well as mutual partnerships help firms maintain their competitive edge.
In June 2022, Roche announced the launch of human papillomavirus (HPV) self-sampling solution. This new solution enables a patient to privately collect samples for HPV screening. The clinically-validated vaginal sample is analyzed with the Roche cobas® HPV test and In June 2020, Merck known as MSD, announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for GARDASIL9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58
Centers for Disease Control and Prevention (CDC) is the regulatory body for Sexually transmitted diseases (STDs), this regulation can serve as facilitators to public health goals. CDC has various legal and policy resources, assessments, public health research, and policy reviews regarding TB, HIV, and other STDs.
Increasing Research and Development in HPV
Market Growth Drivers:
Increasing Prevalence of Sexual Transmitted Infection and Increasing Initiatives by Government & Private Organizations
Lack of Awareness of HPV amongst Population
Limited Number of Treatment Option
Development of Oral Vaccines for HPV
AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.
Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Human Papillomavirus Therapeutics Market
- Analysis about New Entrants in Human Papillomavirus Therapeutics Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators
Against this Challenging Backdrop, Human Papillomavirus Therapeutics Study Sheds Light on
The Human Papillomavirus Therapeutics Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Human Papillomavirus Therapeutics industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
Where Human Papillomavirus Therapeutics industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.